Airway effects of salmeterol in healthy individuals
(1995) In Pulmonary Pharmacology 8(6). p.283-288- Abstract
- The long-acting beta 2-agonist salmeterol has been shown in several in vitro studies to produce non-beta-mediated relaxant effects. The aim of the present study was to investigate whether these effects have any relevance in humans in vivo. Thirteen healthy individuals were studied in a randomized, double-blind, cross-over study on five separate days. The subjects were pre-treated orally with either propranolol 400 mg in order to block beta-adrenoceptor mediated effects or placebo. Two hours after drug intake, three increasing doses of salmeterol (25 + 50 + 100 micrograms), salbutamol (100 + 200 + 400 micrograms) or placebo were given from matched meter dose inhalers at 1-h intervals between doses. Specific airway conductance (sGAW) was... (More)
- The long-acting beta 2-agonist salmeterol has been shown in several in vitro studies to produce non-beta-mediated relaxant effects. The aim of the present study was to investigate whether these effects have any relevance in humans in vivo. Thirteen healthy individuals were studied in a randomized, double-blind, cross-over study on five separate days. The subjects were pre-treated orally with either propranolol 400 mg in order to block beta-adrenoceptor mediated effects or placebo. Two hours after drug intake, three increasing doses of salmeterol (25 + 50 + 100 micrograms), salbutamol (100 + 200 + 400 micrograms) or placebo were given from matched meter dose inhalers at 1-h intervals between doses. Specific airway conductance (sGAW) was measured in a body plethysmograph at the beginning of the experiment and 30 and 60 min after each inhaled dose of the beta-agonists. Salmeterol and salbutamol produced the same maximal increase in sGAW and had the same area under the dose-response curves. Pre-treatment with propranolol totally inhibited the effect of both drugs. In conclusion, salmeterol at clinically used doses did not produce any non-beta-mediated bronchodilating effect in normal individuals, measured as sGAW. Salmeterol and salbutamol showed the same efficacy but salmeterol was four times more potent than salbutamol. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1109390
- author
- Bergendal, Anna ; Johansson, Åke ; Bake, Björn ; Lotvall, Jan ; Skoogh, Bengt-Eric and Löfdahl, Claes-Göran LU
- organization
- publishing date
- 1995
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Salmeterol, sGAw, Potency, Non-β-mediated relaxation, Salbutamol
- in
- Pulmonary Pharmacology
- volume
- 8
- issue
- 6
- pages
- 283 - 288
- publisher
- Elsevier
- external identifiers
-
- pmid:8819183
- scopus:0029556603
- ISSN
- 0952-0600
- DOI
- 10.1006/pulp.1995.1038
- language
- English
- LU publication?
- yes
- id
- e94fa116-d5a2-4530-bceb-b1e4fae104d0 (old id 1109390)
- date added to LUP
- 2016-04-01 17:00:27
- date last changed
- 2021-01-03 10:45:41
@article{e94fa116-d5a2-4530-bceb-b1e4fae104d0,
abstract = {{The long-acting beta 2-agonist salmeterol has been shown in several in vitro studies to produce non-beta-mediated relaxant effects. The aim of the present study was to investigate whether these effects have any relevance in humans in vivo. Thirteen healthy individuals were studied in a randomized, double-blind, cross-over study on five separate days. The subjects were pre-treated orally with either propranolol 400 mg in order to block beta-adrenoceptor mediated effects or placebo. Two hours after drug intake, three increasing doses of salmeterol (25 + 50 + 100 micrograms), salbutamol (100 + 200 + 400 micrograms) or placebo were given from matched meter dose inhalers at 1-h intervals between doses. Specific airway conductance (sGAW) was measured in a body plethysmograph at the beginning of the experiment and 30 and 60 min after each inhaled dose of the beta-agonists. Salmeterol and salbutamol produced the same maximal increase in sGAW and had the same area under the dose-response curves. Pre-treatment with propranolol totally inhibited the effect of both drugs. In conclusion, salmeterol at clinically used doses did not produce any non-beta-mediated bronchodilating effect in normal individuals, measured as sGAW. Salmeterol and salbutamol showed the same efficacy but salmeterol was four times more potent than salbutamol.}},
author = {{Bergendal, Anna and Johansson, Åke and Bake, Björn and Lotvall, Jan and Skoogh, Bengt-Eric and Löfdahl, Claes-Göran}},
issn = {{0952-0600}},
keywords = {{Salmeterol; sGAw; Potency; Non-β-mediated relaxation; Salbutamol}},
language = {{eng}},
number = {{6}},
pages = {{283--288}},
publisher = {{Elsevier}},
series = {{Pulmonary Pharmacology}},
title = {{Airway effects of salmeterol in healthy individuals}},
url = {{http://dx.doi.org/10.1006/pulp.1995.1038}},
doi = {{10.1006/pulp.1995.1038}},
volume = {{8}},
year = {{1995}},
}